The FACT Community Continues to Grow in Numbers of Accredited Organizations and Inspectors
The footprint of FACT accreditation continues to grow around the world. More organizations continue to pursue accreditation as part of their commitment to quality and safe cellular therapy for their patients. This increase in demand, and FACT’s enhanced abilities to support it in a thorough and efficient manner, is directly supported by our prestigious volunteer inspectorate. We extend our genuine appreciation to FACT’s record number of 261 active inspectors. We are also grateful to the many inspector trainees who have attended in-person training sessions so far this year, with many more planning to attend upcoming training courses.
As of May 4, 2026, there are 337 FACT-accredited cellular therapy programs and cord blood banks spanning 27 countries around the globe, with 10 programs achieving initial accreditation in the first four months of the year. We currently have 53 cellular therapy applicants and 4 cord blood applicants in the accreditation process. This includes applicant community-based IEC programs. The following table outlines the progress of the first wave of community-based IEC programs seeking or achieving accreditation:
Please join us in congratulating the following organizations who have achieved initial accreditation so far in 2026:
American Red Cross Puerto Rico Region, San Juan, Puerto Rico
Cellular Therapy Product Collection by Apheresis for Administration and Further Manufacturing, and Cellular Therapy Product Processing with Minimal Manipulation
City of Hope Atlanta, Newnan, Georgia
Adult Autologous Hematopoietic Progenitor Cell Transplantation, Immune Effector Cellular Therapy, Cellular Therapy Product Collection by Apheresis for Administration and Further Manufacturing, and Cellular Therapy Product Processing with Minimal Manipulation
Grupo GSH, São Paulo, Brazil
Marrow Cellular Therapy Product Collection for Administration; Cellular Therapy Product Collection by Apheresis for Administration and Further Manufacturing; and Cellular Therapy Product Processing with Minimal Manipulation
Hoag Family Cancer Institute
Immune Effector Cellular Therapy and Apheresis for Further Manufacturing
Hospital Auxilio Mutuo Bone Marrow Transplant and Cellular Immunotherapy Program, San Juan, Puerto Rico
Adult Allogeneic and Autologous Hematopoietic Progenitor Cell Transplantation, Immune Effector Cellular Therapy, Marrow Cellular Therapy Product Collection for Administration, Cellular Therapy Product Collection by Apheresis for Administration and Further Manufacturing, and Cellular Therapy Product Processing with Minimal Manipulation
KK Women’s and Children’s Hospital, Blood Marrow Transplant and Cellular Therapy (BMTCT) Programme, Singapore, Singapore
Pediatric Allogeneic and Autologous Hematopoietic Progenitor Cell Transplantation; Immune Effector Cellular Therapy; Marrow Cellular Therapy Product Collection for Administration; Cellular Therapy Product Collection by Apheresis for Administration and Further Manufacturing; Cellular Therapy Product Processing with Minimal Manipulation
The MetroHealth System, Cleveland, Ohio
Adult Allogeneic and Autologous Hematopoietic Progenitor Cell Transplantation, Immune Effector Cellular Therapy, Cellular Therapy Product Collection by Apheresis for Administration and Further Manufacturing, and Cellular Therapy Product Processing with Minimal Manipulation
OhioHealth Blood and Marrow Transplant Program
Adult Allogeneic and Autologous Hematopoietic Progenitor Cell Transplantation, Immune Effector Cellular Therapy, Marrow Cellular Therapy Product Collection for Administration, Cellular Therapy Product Collection by Apheresis for Administration and Further Manufacturing, and Cellular Therapy Product Processing with Minimal Manipulation
Ramaiah Memorial Hospital, Bengalaru, Karnataka, India
Adult and Pediatric Allogeneic and Autologous Hematopoietic Progenitor Cell Transplantation, Cellular Therapy Product Collection by Apheresis for Administration, and Cellular Therapy Product Processing with Minimal Manipulation
Royal North Shore Hospital Bone Marrow Transplant and Cellular Therapies Program, St Leonards, New South Wales, Australia
Adult Allogeneic and Autologous Hematopoietic Progenitor Cell Transplantation, Immune Effector Cellular Therapy, Cellular Therapy Product Collection by Apheresis for Administration and Further Manufacturing, and Cellular Therapy Product Processing with Minimal
